Angiogenesis in human gliomas: prognostic and therapeutic implications.
Johnson
J P
JP
Department of Neurological Surgery, Neurological Institute of New York, College of Physicians and Surgeons of Columbia University, New York 10032, USA.
Bruce
J N
JN
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000098:blood supply* / Q000473:pathology / Q000628:therapy*; D003510:Cyclohexanes; D016228:Endothelial Growth Factors / Q000502:physiology; D004815:Epidermal Growth Factor / Q000502:physiology; D016220:Fibroblast Growth Factor 1 / Q000502:physiology; D016222:Fibroblast Growth Factor 2 / Q000502:physiology; D005910:Glioma / Q000098:blood supply* / Q000473:pathology / Q000628:therapy*; D006801:Humans; D008222:Lymphokines / Q000502:physiology; D009389:Neovascularization, Pathologic / Q000517:prevention & control; D000077609:O-(Chloroacetylcarbamoyl)fumagillol; D011379:Prognosis; D012717:Sesquiterpenes / Q000627:therapeutic use; D013498:Suramin / Q000627:therapeutic use; D016211:Transforming Growth Factor alpha / Q000502:physiology; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D000970:Antineoplastic Agents; D003510:Cyclohexanes; D016228:Endothelial Growth Factors; D008222:Lymphokines; D012717:Sesquiterpenes; D016211:Transforming Growth Factor alpha; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D016222:Fibroblast Growth Factor 2; D016220:Fibroblast Growth Factor 1; D013498:Suramin; D004815:Epidermal Growth Factor; D000077609:O-(Chloroacetylcarbamoyl)fumagillol